NPSP

First suggested here at $6.65 and then again at $5.50 or so, NPSP closed Friday at $22.59, for about a quadruple. I celebrated by taking some profits; yet Guru writes of the company’s wildly expensive drug ($295,000 a year): “There are probably 1,000 to 3,000 people in the US who could really benefit from Gattex. Could be more. That’s $300 million to $900 million in the US. They will launch in Europe where the market is similarly sized. For sure this is a $500 million in peak sales. Every year. For a long time. No competition. No one even trying to compete. This product could extend survival. Meanwhile, they have another product, for hypoparathyroidism — to supply the missing parathyroid hormone. Will file this year. Launch end of next year. Another $300 million potential market in the US. Then they get a royalty from Amgen of $100 million. The stock should hit 36 over the next year.” So I’ve kept some.

Yesterday, it closed at $35.11, which is close enough. I took my six-fold gain (thanks, Guru) and sold the rest.

Have a great day. I feel a political screed coming on, but for now, you’re spared.

Quote of the Day

It was only 80 years from the time Darwin published ON THE ORIGIN OF SPECIES until we detonated the first nuclear bomb. In the lifetime of one person, we went from figuring out where we came from to figuring out how to get rid of ourselves.

~Paleontologist Jack Horner

Search

Request email delivery

Email Address*

First Name

Last Name

* = required field

Advice

"So full of tips and angles that only a booby or a billionaire could not benefit." -- The New York Times